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KONSTANTIN B. KONSTANTINOV 
 
 
Engineering Conferences International (ECI) is very pleased to announce the creation of an award 
for the very successful conference series on Integrated Continuous Biomanufacturing (ICB). The 
first award will be given to Konstantin Konstantinov in recognition of his vision and effort to create 
this conference series and for his multiple contributions to the field.  This award will be presented 
to Konstantin at ICB III.  
 
Konstantin will give a keynote lecture and chair a committee to select future winners of this award.  
 
Konstantin continues to makes differentiating contributions to process development and 
commercialization activities for multiple new products through his over 50 Peer Reviewed 
publications and his many conference contributions.  This activity was recently recognized by the 
Cell Culture Engineering (CCE) community and Konstantin was selected from many contenders as 
the 2016 recipient of the Conference award which was presented to him in May at CCE XV in La 
Quinta, California.  
 
We anticipate that the Integrated Continuous Biomanufacturing Conference will grow in importance 
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 Technical Sessions will be in Rooms I and II. Poster sessions will be in Room III. 
 All meals will be on the 3rd Floor, with the exception of the conference banquet on Wednesday.  
 The ECI office will be in Room XI. 
 The gala dinner will be in Rooms I and II. 
 Workshop locations will be announced on site. 
 Audio, still photo and video recording by any device (e.g., cameras, cell phones, laptops, PDAs, watches) 
is strictly prohibited during the technical sessions, unless prior permission has been granted by the author 
and ECI.  
 Speakers – Please have your presentation loaded onto the conference computer prior to the session start 
(preferably the day before). 
 Speakers – Please leave at least 3-5 minutes for questions and discussion.  
 Please do not smoke at any conference functions. 
 Turn your mobile telephones to vibrate or off during technical sessions. 
 Please write your name on your program so that it can be returned to you if lost or misplaced. 
 After the conference, ECI will send an updated participant list to all participants. Please check your listing 




Workshop 1:  Increasing Speed to Clinic with Continuous Biomanufacture 
Chairs: Todd Przybycien, Carnegie Mellon University, USA 
 Jon Coffman, Boehringer Ingelheim Pharma, USA  
 
Workshop 2:  Evaluating Future Facility Design Concepts 
Chairs: Suzanne Farid, University College London, United Kingdom 
 Michael Borys, Bristol-Myers Squibb, USA 
 
Workshop 3:  Gearing Up for Process Performance Qualification Readiness for ICB 
Chairs: Mark Brower, MSD, USA 
 Jeff Salm, Pfizer, USA 
 
Workshop 4:  Industry-Academia-Vendor-Government Collaboration in the ICB 
Space 
Chairs: Alessandro Butte, ETH Zurich, Switzerland 






Sunday, September 17, 2017 
 
14:00 – 16:15  Conference Check-in  
    
16:15 – 16:30  Welcome – Conference Chairs and ECI Liaison 
  
16:30 – 17:15  Keynote Lecture 1 
Are we prepared to meet the demands of a challenging, but promising future? 
James Thomas, Just Biotherapeutics, Inc. USA 
 
17.15 – 17.45  Break 
 
17:45 – 19:15  Workshops (2 in parallel) 
 
Workshop 2:  Evaluating Future Facility Design Concepts (XII+XIII) 
Chairs: Suzanne Farid, University College London, United Kingdom 
    Michael Borys, Bristol-Myers Squibb, USA 
 
Workshop 3:  Gearing Up for Process Performance Qualification Readiness for ICB 
(XV) 
Chairs: Mark Brower, MSD, USA 
 Jeff Salm, Pfizer, USA 
 
 
19:30 – 21:30  Dinner 
 
 




Monday, September 18, 2017 
 
07:30 – 09:00 Breakfast 
  
Session 1: Continuous Culture to Capture 
(Sponsored by Pfizer) 
Chairs:  Martina Micheletti, University College London (UCL), United Kingdom 
Jason Walther, Sanofi, USA. Thomas Ryll, Immunogen, USA 
 
09:00 – 09:25 Continuous bioprocessing for biologics manufacturing 
Weichang Zhou, WuXi Biologics, China  
 
09:25 – 09:50 Development of highly intensified cell culture perfusion media and process with 
tremendous productivity potential, while having a low cell bleed requirement for 
maintaining an overall high yield 
Henry Lin, Boehringer Ingelheim, USA 
 
09:50 – 10:15 Scalable technologies for process intensification in the continuous 
biomanufacturing factories of the future 
Gerben Zijlstra, Sartorius, Germany 
 
10:15 – 10:40 Process development in screening scale bioreactors and perspectives for very high 
cell density perfusion 
Veronique Chotteau, KTH, Sweden 
 
10:40 – 11:05 Evaluating options objectively – Resisting the "purist" approach to arrive at the 
most productive, robust, and practically implementable perfusion utilizing 
processes 
Gregory Hiller, Pfizer, Inc., USA 
 
11:05 – 11:45 Coffee / Networking Break 
 
11:45 – 12:30 Keynote Lecture 2 
Systemic rejuvenation: From blood to molecular therapies  
Ludwig Aigner, Paracelsus Medical University Salzburg, Austria 
 
12:30 – 13:45 Lunch  
 
   Session 2: Continuous Purification and Drug Product Sequences 
(Sponsored by Amgen) 
Chairs: Manuel Carrondo, iBET, Portugal 
    Art Hewig, Amgen, USA 
 
13:45 – 14:10 Development of continuous production and purification processes for the integrated 
manufacture of monoclonal antibodies 
Massimo Morbidelli, ETH Zürich, Switzerland   
 
14:10 – 14:35 From development to implementation with a fully integrated downstream bioprocess 
Jeff Salm, Pfizer, USA 
 
14:35 – 15:00 Process intensification: Enabling technologies and methodologies 
Jean-Marc Bielser / Jonathan Souquet, Merck KGaA, Switzerland 
 
15:00 – 15:25 A disruptive alternative to semi-continuous multi-column chromatography (MCC) 
processes 
Michael Rose, UCB, United Kingdom 
 
15:25 – 15:50 Multi-column chromatographic purification of influenza virus-like particles 
Ricardo Silva, iBET, Portugal  
Monday, September 18, 2017 (continued) 
 
15:50 – 16:45 Coffee / Networking Break 
 
16:45 – 18:00 Poster Snapshot Session  
 Chairs: Alois Jungbauer, BOKU, Austria 
  Veronique Chotteau, KTH, Sweden 
  Natalia Gomez, Amgen, USA 
  Jarno Robin, Sanofi, France 
 
16:45 – 16:50 Fouling mitigation in membrane based perfusion systems by oscillating tangential 
flow 
Maria Weinberger, Technical University of Munich, Germany 
 
16:50 – 16:55 Bioprocess intensification and optimisation using macroscopic predictive models of 
cell culture processes 
Bassem Ben Yahia, UCB Pharma S.A., Belgium 
 
16:55 – 17:00 Use of a biphasic perfusion process based on mild hypothermia for recombinant 
glucocerebrosidase (GBA) production 
Filipa Gonçalves, Instituto Superior Técnico, Portugal 
 
17:00 – 17:05 Ultra scale-down mimics for perfusion culture: Experimental study for rapid 
biopharmaceutical process development 
Molly Tregidgo, University College London, United Kingdom 
 
17:05 – 17:10 Evaluation of pseudo-perfusion feeding strategies for mAb production using a CHO 
cell line adapted to concentrated feed media 
Leda Castilho, Federal University of Rio de Janeiro, Brazil 
 
17:10 – 17:15 Conversion of an industrial batch separation process to an autonomous integrated 
downstream process – A case study 
Anton Lofgren, Lund University, Sweden 
 
17:15 – 17:20 Continuous protein precipitation – A robust antibody purification method without 
the need for steady state conditions during continuous integrated production. 
Daniel Burgstaller, University of Natural Resources and Life Sciences, Vienna, Austria 
 
17:20 – 17:25 Continuous extraction strategies for monoclonal antibodies: From macro- to micro-
scale 
Ana Margarida Azevedo, Instituto Superior Técnico, Portugal 
 
17:25 – 17:30  Design of a novel continuous flow reactor for low pH viral inactivation 
Stephanie A. Parker, Keck Graduate Institute, USA 
 
17:30 – 17:35  Supervisory control of integrated continuous downstream processes 
Bernt Nilsson, Lund University, Sweden 
 
17:35 – 17:40 Digitalization platform and supervisory control of a continuous integrated 
bioprocess based on Raman spectroscopy 
Fabian Feidl, ETH Zürich, Switzerland 
 
17:40 – 17:45 Up and down scale considerations for the continuous production of glycooptimized 
biopharmaceuticals 
Vicky Goralczyk, Glycotope GmbH, Germany 
 
17:45 – 17:50 Scalable lentiviral vector production using stable producer cell lines in perfusion 
mode 
Aziza Manceur, National Research Council Canada, Canada 
Monday, September 18, 2017 (continued) 
 
17:50 – 17:55 Continuous gas processing without bubbles using thin liquid film bioreactors 
containing biocomposite biocatalysts 
Michael C. Flickinger, North Carolina State University, USA 
 
17:55 – 18:00 Enabling next-generation cell line development using continuous perfusion and 
nanofluidic technologies 
Chetan Goudar, Amgen, USA 
 
18:00 – 19:00 Free Time 
 
19:00 – 20:30 Dinner 
 






Tuesday, September 19, 2017 
 
07:30 – 09:00 Breakfast 
 
   Session 3: End-to-end Continuous Biomanufacture  
(Sponsored by Boehringer Ingleheim) 
   Chairs: Massimo Morbidelli, ETH Zurich, Switzerland 
    Rohan Patil, Sanofi, USA 
 
09:00 – 09:25  Towards the implementation of a continuous bioprocess in single use technology 
Jorgen Magnus / Thomas Daszkowski, Bayer, Germany  
 
09:25 – 09:50 Implementation of an end-to-end continuous bioprocessing platform using novel 
technologies 
Peter Levison, Pall Life Sciences, United Kingdom 
 
09:50 – 10:15 Fully integrated continuous antibody processing demonstrates improved 
productivity 
Kenneth Lee, MedImmune LLC, USA 
 
10:15 – 10:40 Balancing continuous, integrated, and batch processing 
Jonathan Coffman, Boehringer Ingelheim, USA 
 
10:40 – 11:05 Continuous freeze-drying and its relevance to the pharma/biotech industry 
Roberto Pisano, Politecnico di Torino, Italy 
 
11:05 – 11:45 Coffee / Networking Break 
 
11:45 – 12:30 Keynote Lecture 3 
 Continuous manufacturing - EMA perspective and experience 
   Nino Mihokovic, European Medicines Agency, United Kingdom 
 
12:30 – 13:30 Lunch  
 
13:30 – 15:00 Poster Session with dessert and Social Hour 
 Chairs: Alois Jungbauer, BOKU, Austria 
  Veronique Chotteau, KTH, Sweden 
  Natalia Gomez, Amgen, USA 
  Jarno Robin, Sanofi, France 
 




Wednesday, September 20, 2017 
 
07:30 – 09:00 Breakfast 
  
Session 4:  Predictive Continuous QbD Case Studies 
(Sponsored by Sartorius Stedim Biotech) 
 Chairs: Naz Karim, Texas A&M University, USA 
Dorothee Ambrosius, Boehringher Ingelheim Pharma, Germany 
 
09:00 – 09:25 Continuous bioprocessing and process analytical technologies: A path towards 
quality by design 
Nuno Pinto, Merck & Co., Inc., USA 
 
09:25 – 09:50 Commercialization of a 2nd generation intensified perfusion process during life 
cycle management 
Jiuyi Lu, Sanofi, USA 
 
09:50 – 10:15 Regulatory aspects of continuous downstream processing 
Marc Bisschops, Pall Corporation, Netherlands 
 
10:15 – 10:40 Integrating analysis with process control for continuous bioprocessing: Extending 
the lifecycle concept to process analytical technologies 
Jose Menezes, Instituto Superior Tecnico & 4Tune Engineering Ltd, Portugal 
 
10:40 – 11:05 A comprehensive study in PAT-applications for a QbD-compliant development of 
continuous biopharmaceutical production 
Reiner Luttmann, Hamburg University of Applied Sciences, Germany 
 
11:05 – 11:45 Coffee / Networking Break 
 
11:45 – 13.15 Workshops (2 in parallel) 
 
Workshop 1:  Increasing Speed to Clinic with Continuous Biomanufacture (XII+XIII) 
Chairs: Todd Przybycien, Carnegie Mellon University, USA 
 Jon Coffman, Boehringer Ingelheim Pharma, USA  
 
Workshop 4:  Industry-Academia-Vendor-Government Collaboration in the ICB 
Space (XV) 
Chairs: Alessandro Butte, ETH Zurich, Switzerland 
 Alex Xenopoulos, EMD Millipore, USA 
 
13:15 – 14:30 Lunch  
 
Session 5:  Business Case for Facilities of the Future 
(Sponsored by Merck) 
Chairs: Alex Kiparissides / Nigel Titchener-Hooker, University College London (UCL), 
United Kingdom 
 Thomas Sauer, Sanofi, Germany 
 
14:30 – 14:55 Delivering a toolbox of flexible platforms for clinical and commercial bioprocessing 
production: ‘Defining the business drivers for development and implementation’ 
Mark Brower, Merck & Co Inc, USA 
 
14:55 – 15:20 Are integrated processes a solution looking for a problem to solve, or a tool to solve 
the problem? 
Joseph Shultz, Novartis Pharma AG, Switzerland 
 
15:20 – 15:45 Process economics in biologics manufacturing 
John Machulski, Sanofi, USA  
Wednesday, September 20, 2017 (continued) 
 
15:45 – 16:10 Next generation manufacturing for biologics: Integration of a hybrid model for 
continuous manufacturing concepts into a clinical facility 
   Michael Borys, Bristol-Myers Squibb, USA 
 
16:10 –16:30 Coffee / Networking Break 
 
Session 6: Continuous Biomanufacture Beyond CHO or Proteins  
(Sponsored by GE Healthcare) 
Chairs: Chris Love, Massachusetts Institute of Technology, USA 
 Uwe Gottschalk, Lonza, Switzerland 
 
16:30 – 16:55 Beyond CHO – Non-mammalian hosts could be the future expression systems of 
choice for recombinant biotherapeutics 
Chapman Wright, Biogen, USA 
 
16:55 – 17:20 Integrated manufacturing with microbial hosts for fast process development and 
production 
J. Christopher Love, Massachusetts Institute of Technology, USA 
 
17:20 – 17:45 Continuous biomanufacturing concepts for cell therapy processes 
Erika M. McAfee, Lonza Walkersville, Inc., USA 
 
17:45 – 18:10 Bioprocess intensification for the continuous expansion of 3D human induced 
pluripotent stem cell aggregates in bioreactors 
Bernardo Abecasis, IBET, Portugal 
 
18:10 –18:25 Stretch Break 
 
18:25 – 19:00 Keynote Lecture 4 (ICB Award Lecture) 
 Development and large scale manufacturing of exosome-based therapeutics 
Konstantin Konstantinov, Codiak Biosciences, USA 
 
19:00  – 19:45  Free Time 
 
 
19:45  – 20:30 Reception 
 
 
20:30 – 22:30 Conference Banquet and Awards  
 
 






Thursday, September 21, 2017 
 






                Continuous Culture to Capture 
 
1. Optimizing media for perfusion combining predictive scale-down models and 
multivariate approaches 
Jochen Sieck, Merck KGaA, Germany 
 
2. Development of a scale down toolbox for perfusion process development 
Jean-Marc Bielser, Merck KGaA, Switzerland 
 
3. Development and application of screening scale bioreactor systems for very high cell 
density perfusion of mammalian cells 
Caijuan Zhan, KTH - Cell Technology Group (CETEG), Sweden 
 
4. Fouling mitigation in membrane based perfusion systems by oscillating tangential flow 
Maria Weinberger, Technical University of Munich, Germany 
 
5. Bioprocess intensification and optimisation using macroscopic predictive models of 
cell culture processes 
Bassem Ben Yahia, UCB Pharma S.A., Belgium 
 
6. Ultra scale-down mimics for perfusion culture: Experimental study for rapid 
biopharmaceutical process development 
Molly Tregidgo, University College London, United Kingdom 
 
7. Evaluation of pseudo-perfusion feeding strategies for mAb production using a CHO 
cell line adapted to concentrated feed media 
Leda Castilho, Federal University of Rio de Janeiro, Brazil 
 
8. Use of a biphasic perfusion process based on mild hypothermia for recombinant 
glucocerebrosidase (GBA) production 
Filipa Gonçalves, Instituto Superior Técnico, Portugal 
 
9. Enhancing crispr-mediated CHO cell antibody productivity through concentrated fed-
batch or continuous perfusion 
Ching-Jen Yang, Development Center for Biotechnology, Taiwan 
 
10. Evaluation of cell culture with a simulated continuous manufacturing (sCM) process in 
50mL tubespins for clone selection 
Natalia Gomez, Amgen, USA 
 
11. Screening cell growth in simulated continuous manufacturing spin tubes determines 
optimal media conditions for cell lines 
Jonathan Lull, Amgen, USA 
 
12. Development of a novel automated perfusion mini bioreactor ‘ambr® 250 perfusion’ 
Barney Zoro, Sartorius Royston, United Kingdom 
 
13. More than 15 years of continuous processing using chemostat cultures. A Shire niche? 
Daniel Fleischanderl, Shire, Austria 
 
14. Small-scale development and optimization of stirred tank mammalian cell perfusion 
cultures 
Moritz Wolf, ETH Zurich, Switzerland 
 
15. Intensification of a multi-product perfusion platform through medium and process 
development 
Shawn Barrett, Sanofi, USA 
 
16. Computational Fluid Dynamics (CFD) modelling and experimental confirmation of 
hollow fiber tangential flow filtration (HFTFF) and alternating tangential flow filtration 
(ATF) In a perfusion bioreactor 
Flaka Radoniqi, Keck Graduate Institute and Boehringer Ingelheim, USA 
 
17. Up and down scale considerations for the continuous production of glycooptimized 
biopharmaceuticals 
Vicky Goralczyk, Glycotope GmbH, Germany 
 
18. Ultra scale-down concepts to address early stage process development challenges in 
integrated continuous bioprocessing 
Andrea Rayat, University College London, United Kingdom 
 
 
Continuous Purification and Drug Product Sequences 
 
19. Continuous protein precipitation – A robust antibody purification method without the 
need for steady state conditions during continuous integrated production 
Daniel Burgstaller, University of Natural Resources and Life Sciences, Vienna, Austria 
 
20. Continuous in-line virus inactivation for next generation bioprocessing 
Melissa Holstein, MilliporeSigma, USA 
 
21. Consideration of filter design space for validation of virus filtration in continuous 
processing applications 
Nigel Jackson, Pall Life Sciences, United Kingdom 
 
22. Impact of product and recycle times in MCSGP polishing on charge variant separation 
Sebastian Vogg, ETH Zurich, Switzerland 
 
23. Novel single-column simulated moving-bed chromatography platform for quasi-
continuous biopurification 
José P. B. Mota, LAQV-REQUIMTE, FCT-UNL, Portugal 
 
24. Design of a novel continuous flow reactor for low pH viral inactivation 
Stephanie A. Parker, Keck Graduate Institute, USA 
 
25. Progress towards continuous aqueous two-phase extraction via TAPPIR 
Andreas Bommarius, Georgia Institute of Technology, USA 
 
26. Continuous extraction strategies for monoclonal antibodies: From macro- to micro-
scale 
Ana Margarida Azevedo, Instituto Superior Técnico, Portugal 
 
27. Enabling end-to-end continuous biomanufacturing by exploring integration approaches 
of continuous TFF 
Eva Udovic, University of Ljubljana, Slovenia 
 
28. Viral clearance considerations for continuous viral inactivation 
Raquel Orozco, Boehringer Ingelheim, USA 
 
29. Conversion of an industrial batch separation process to an autonomous integrated 
downstream process – A case study 
Anton Lofgren, Lund University, Sweden 
 
30. Much-efficient and cost-effective manufacturing of antibody biotherapeutics employing 
integrated negative chromatography technology 
Razwan Hanif, UCB, United Kingdom 
 
31. A fully continuous downstream process concept without column chromatography 
Todd Przybycien, Carnegie Mellon University, USA 
 
32. Dynamic process control of twin-column periodic countercurrent chromatography 
processes 
Thomas Muller-Spath, ETH Zurich, Switzerland 
 
 
End-to-end Continuous Biomanufacture 
 
33. Application of single pass TFF to enable intensified and continuous biological 
manufacturing 
Herbert Lutz, MilliporeSigma, USA 
 
34. Development of an N-1 perfusion process and optimized scale-down models for 
implementation in a platform CHO cell culture manufacturing process 
Frank V. Ritacco, Bristol-Myers Squibb, USA 
 
35. Process considerations for Protein A affinity capture, virus inactivation, and linked 
polishing steps in multi-column continuous purification of monoclonal antibodies 
Robert Mierendorf, Semba Biosciences, Inc., USA 
 
36. Continuous purification of monoclonal antibody using periodic counter-current 
chromatography 
Wei-Kuang Chi, Development Center for Biotechnology, Taiwan 
 
37. Clarification and capture of a CHO-derived monoclonal antibody through flocculation 
and AEX processes 




Predictive Continuous QbD Case Studies 
 
38. Supervisory control of integrated continuous downstream processes 
Bernt Nilsson, Lund University, Sweden 
 
39. Process analytical technologies for a continuous capture and connected downstream 
process 
Nina Brestrich/Joseph Shultz, Novartis Pharma AG, Switzerland 
 
40. Digitalization platform and supervisory control of a continuous integrated bioprocess 
based on raman spectroscopy 
Fabian Feidl, ETH Zürich, Switzerland 
 
41. Process analytical technology (PAT) in continuous bioprocessing 
Edita Botonjic-Sehic, Pall Life Sciences, USA 
 
42. Qualification of single use in-line sensors for use in continuous bioprocessing 
James Furey, PendoTECH, USA 
 
43. Time-series datamining for continuous bioprocess analysis 
Yang Yang, University College London, United Kingdom 
 
44. Enhancing multivariate calibration model reproducibility for the online monitoring of 
upstream processes in continuous biomanufacturing 
Nicholas A. Trunfio, University of Massachusetts - Lowell, U.S. Food and Drug Administration, 
USA 
 
45. FDA/OBP laboratory research to support continuous bioprocessing 
Scott Lute, U.S. FDA, CDER/OBP, USA 
 
 
Business Case for Facilities of the Future 
 
46. Cost modeling of an integrated, continuous downstream mAb platform 
Mark Schofield, Pall Life Sciences, USA 
 
47. Facility design concepts for adoptive T-cell immunotherapy 
Tania Pereira Chilima, UCL, United Kingdom 
 
 
Continuous Biomanufacture Beyond CHO or Proteins 
 
48. Continuous desalting of refolding solution by ion exchange chromatography 
Nicole Walch, Austrian Centre of Industrial Biotechnology, Austria 
 
49. Continuous gas processing without bubbles using thin liquid film bioreactors 
containing biocomposite biocatalysts 
Michael C. Flickinger, North Carolina State University, USA 
 
50. Novel concepts for efficient and predictable membrane separation in continuous cell 
retention and downstream processing 
Ulrich Kulozik, Technical University of Munich, Germany 
 
51. Stirred tanks in cascades and plug-flow tubular bioreactors for continuous production 
of viral vaccines 
Felipe Tapia, Max Planck Institute for Dynamics of Complex Technical Systems, Germany 
 
52. Scalable lentiviral vector production using stable producer cell lines in perfusion mode 
Aziza Manceur, National Research Council Canada, Canada 
 
53. Continuous chromatography beyond affinity capture of monoclonal antibodies 
Linda Mathiasson, GE Healthcare, Sweden 
 
54. Enabling next-generation cell line development using continuous perfusion and 
nanofluidic technologies 




Sun. Sep 17 Mon. Sep 18 Tues. Sep 19 Wed. Sep 20 Thur. Sep 21
07:30-09:00         
Breakfast
07:30 - 09:00       
Breakfast
07:30 - 09:00       
Breakfast
06:30 - 09:30       
Breakfast & Departures
11:05 - 11:45 
Coffee/Networking Break
11:05 - 11:45 
Coffee/Networking Break
11:05 - 11:45 
Coffee/Networking Break
11:45 - 12:30               
Keynote 2
11:45 - 12:30               
Keynote 3
11:45 - 13:15                
Workshops  
(2 in parallel)
12:20 - 13:45              
Lunch
12:30 - 13:30                 
Lunch
13:15 - 14:30               
Lunch
14:00 - 16:15    
Conference Check-in
13:45 - 15:50               
Session 2:       
Continuous Purification 
and Drug Product 
Sequences
13:30 - 15:00          
Poster Session with 
dessert
14:30 - 16:10          
Session 5:  
Business Case for 
Facilities of the Future
16:15 - 16:30       
Welcome - Conference 
Chairs & ECI Liaison
15:50 - 16:45 
Coffee/Networking Break
16:10 - 16:30 
Coffee/Networking Break
16:30 - 17:15          
Keynote 1
17:15 - 17:45                
Break
18:10 - 18:25              
Stretch Break 
18:25 - 19:00          
Keynote 4 
(ICB Award Lecture)
19:00 - 19:45            
Free Time
19:45 - 20:30               
Reception
20:30 - 22:30              
Conference Banquet & 
Awards
22:30 - 23:30                
Social Hour
19:00 - 20:30                
Dinner
21:30 - 23:00             
Social Hour
20:30 - 22:30           
Poster Session with 
dessert and Social Hour





09:00 - 11:05             
Session 4:  
Predictive Continuous 
QbD Case Studies
09:00 - 11:05    
Session 1:            
Continuous Culture to 
Capture
15:00 - 22:00            
Excursion and Dinner on 
your own before 
returning to hotel 16:45 - 18:00          
Poster Snapshot Session





17:45 - 19:15   
Workshops 
(2 in parallel)
18:00 - 19:00              
Free Time
19:30 - 21:30            
Dinner
